Literature DB >> 15980382

In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus.

Carolina Serena1, Belkys Fernández-Torres, F Javier Pastor, Luciana Trilles, Márcia Dos Santos Lazéra, Nicole Nolard, Josep Guarro.   

Abstract

The combination of micafungin (MFG) with amphotericin B (AMB), fluconazole, itraconazole, voriconazole, or ravuconazole was evaluated against 37 strains of four species of Cryptococcus by the checkerboard method. Antagonism was never seen. Synergy was observed for some isolates for each combination and was most frequent with MFG-AMB.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15980382      PMCID： PMC1168639          DOI： 10.1128/AAC.49.7.2994-2996.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Rationale for combination antifungal therapy.

Authors:  R E Lewis; D P Kontoyiannis
Journal:  Pharmacotherapy       Date:  2001-08       Impact factor: 4.705

Review 2.  Uncommon opportunistic fungi: new nosocomial threats.

Authors:  A H Groll; T J Walsh
Journal:  Clin Microbiol Infect       Date:  2001       Impact factor: 8.067

3.  Cryptococcal meningitis caused by Cryptococcus neoformans var. gattii, serotype C, in AIDS patients in Soweto, South Africa.

Authors:  A S Karstaedt; H H Crewe-Brown; F Dromer
Journal:  Med Mycol       Date:  2002-02       Impact factor: 4.076

4.  Efficacy of micafungin alone or in combination against systemic murine aspergillosis.

Authors:  Javier Capilla Luque; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

5.  In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

6.  Interactions of posaconazole and flucytosine against Cryptococcus neoformans.

Authors:  F Barchiesi; A M Schimizzi; L K Najvar; R Bocanegra; F Caselli; S Di Cesare; D Giannini; L F Di Francesco; A Giacometti; F Carle; G Scalise; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

7.  Efficacy of micafungin in combination with other drugs in a murine model of disseminated trichosporonosis.

Authors:  Carolina Serena; F Javier Pastor; Félix Gilgado; Emilio Mayayo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

8.  In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens.

Authors:  F Barchiesi; D Arzeni; A W Fothergill; L F Di Francesco; F Caselli; M G Rinaldi; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

9.  Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.

Authors:  A H Groll; D Mickiene; V Petraitis; R Petraitiene; K H Ibrahim; S C Piscitelli; I Bekersky; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

10.  Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.

Authors:  Ellen E Roling; Michael E Klepser; Ashley Wasson; Russell E Lewis; Erika J Ernst; Michael A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  2002-05       Impact factor: 2.803
View more
  5 in total

1.  Inhibition of fungal beta-1,3-glucan synthase and cell growth by HM-1 killer toxin single-chain anti-idiotypic antibodies.

Authors:  Dakshnamurthy Selvakumar; Masahiko Miyamoto; Yasuhiro Furuichi; Tadazumi Komiyama
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp.

Authors:  Carolina Serena; Marçal Mariné; Guillermo Quindós; Alfonso J Carrillo; J F Cano; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

Review 3.  Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment.

Authors:  F P Gullo; S A Rossi; J de C O Sardi; V L I Teodoro; M J S Mendes-Giannini; A M Fusco-Almeida
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-04       Impact factor: 3.267

4.  Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model.

Authors:  Supavit Chesdachai; Radha Rajasingham; Melanie R Nicol; David B Meya; Felix Bongomin; Mahsa Abassi; Caleb Skipper; Richard Kwizera; Joshua Rhein; David R Boulware
Journal:  Open Forum Infect Dis       Date:  2019-10-01       Impact factor: 3.835

Review 5.  Candida Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents.

Authors:  Giselle C de Oliveira Santos; Cleydlenne C Vasconcelos; Alberto J O Lopes; Maria do S de Sousa Cartágenes; Allan K D B Filho; Flávia R F do Nascimento; Ricardo M Ramos; Emygdia R R B Pires; Marcelo S de Andrade; Flaviane M G Rocha; Cristina de Andrade Monteiro
Journal:  Front Microbiol       Date:  2018-07-03       Impact factor: 5.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.